SmartLight slashes prices
Digital light box developer SmartLight has reduced the price of its products by up to 40%, thanks to a significant decrease in the firm’s production costs, according to the Hackensack, NJ-based company. As a result, SmartLight’s entry-level SL
Digital light box developer SmartLight has reduced the price of its products by up to 40%, thanks to a significant decrease in the firms production costs, according to the Hackensack, NJ-based company. As a result, SmartLights entry-level SL 2000Plus product now costs approximately $10,000, while the Smart Motorized Viewer starts as low as $49,000.
In other developments, SmartLight has reported an increase in sales volume, owing to its direct sales efforts and distribution deals with Fuji Medical in Japan and Siemens Medical Systems in Germany (SCAN 6/24/98 and 4/14/99). The company has also opened an expanded manufacturing facility in Yokheam, Israel.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
